Revisit news and research in anemia
New anemia drugs could change the steady state of kidney care
Click Here to Manage Email Alerts
Healio has compiled a list of its most-read anemia care news in 2023.
How drugs may change the treatment of kidney disease caught readers’ attention, as well as articles about patient uptake of new therapies and thrombosis access in chronic kidney disease care.
New anemia drugs could change the steady state of kidney care
During the last 3 decades, only one class of drugs – erythropoiesis-stimulating agents – has been available to treat anemia in patients with end-stage kidney disease. That has now changed. Read more.
Survey shows limited uptake with new anemia drugs
Most nephrologists remain hesitant with prescribing hypoxia-inducible factor-prolyl hydroxylase inhibitors to treat anemia. Read more.
Lower rates of access thrombosis for patients with CKD who receive daprodustat vs. EPO
Patients with chronic kidney disease on dialysis who received daprodustat had fewer vascular access thrombosis events compared with patients who had erythropoiesis-stimulating agents, according to data presented at ASN Kidney Week. Read more.
KDIGO report questions use of iron, raises concerns of inflammation with new anemia drugs
Trials show hypoxia-inducible factor prolyl hydroxylase inhibitors are noninferior to other anemia drugs for patients with dialysis-dependent CKD. Read more.
VIDEO: Treating anemia in cases of severe CKD
Jay B. Wish, MD, discusses anemia in cases of severe chronic kidney disease. Read more.
Collapse
Healio Coverage
Read more about
Click Here to Manage Email Alerts